IBER

Ibere Pharmaceuticals
IBER

Overview Fund Activity
Delisted

IBER was delisted on the 1st of March, 2023.

Back to rankings

47 hedge funds and large institutions have $126M invested in Ibere Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
47
Holders Change
-1
Holders Change %
-2.08%
% of All Funds
0.76%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
7
Reduced
5
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
HSBC Holdings
HSBC Holdings
United Kingdom
$3.28M
2
AC
Aristeia Capital
Connecticut
$6.81M
3
WCMNY
Westchester Capital Management (New York)
New York
$2.46M
4
GCL
Glazer Capital LLC
New York
$13.4M
5
HIM
HGC Investment Management
Ontario, Canada
$495K

Top Sellers

1
CAC
Cowen and Company
New York
$0
2
Citadel Advisors
Citadel Advisors
Florida
$0
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
$1.51M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
$534K
5
PI
PEAK6 Investments
Illinois
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
Barclays
51
Barclays
United Kingdom
– -$486K -49,023 Closed
MSU
52
Mizuho Securities USA
New York
– -$398K -40,333 Closed
VF
53
Virtu Financial
New York
– -$250K -25,238 Closed
EC
54
Elequin Capital
New York
– -$5K -500 Closed
1 2
3